Consistent with the results from mouse studies, we showed that glioma-CM-pretreated human ECs stimulated human monocytes toward alternative activation, as evidenced by increased CD206+CD86+ populations in CD11b+ cells (Fig. 2c). The gene discussed is CD86; the disease is central nervous system cancer.